Codexis

Update in progress

CDXS (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Codexis, Inc. delivers technology for therapeutic manufacturing. Using its CodeEvolver platform, it discovers, develops, improves, and commercializes novel enzymes. The ECO Synthesis platform enables scalable, enzymatic production of RNAi therapeutics. Codexis has license agreements with Aldevron LLC and Pfizer Inc. Founded in 2002, the company is headquartered in Redwood City, California, and serves customers globally.

Company score

Sentiment: 0.39; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.16; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.02; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.22; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive